http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1864995-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26acde46369081547d4007d976afa0e8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0817 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-64 |
| filingDate | 2004-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55a8c72e33d6214f7435e77169485112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8601639a180b7a12d20727b5f540a250 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c40b77bde575561751a0497288a31fd9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3787863e1216c45bde9b92ae1b6a208a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15bc88101b30717262dd21dca552671b |
| publicationDate | 2007-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1864995-A1 |
| titleOfInvention | Beta-lactamic rgd cyclopeptides containing gamma turns |
| abstract | A compound of the formula (I): n n cyclo [Arg-Gly-Asp-(beta-Lactam)] (I) n ncontaining at least one γ turn where (beta-Lactam)- is a fragment of 3-amino-1-(2-carbonylmethyl)-azetidin-2-one of the formula (II)n nwhere R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are selected independently from the group formed by hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, -COR 7 , -C(0)OR 7 , -CO)NR 7 R 8 -C=NR 7 -CN, -OR 7 , - _ OC(O) 7 , -S(O) t -R 7 , -NR 7 R 8 , -NR 7 C(O)R 9 , -NO 2 , -N=CR 7 R 8 or halogen; where two of them can be bridged to form a cyclic substituent; their enantiomers, diastereomers or their pharmaceutically acceptable salts. n These compounds selectively inhibit certain integrins and are useful for the treatment of diseases such as cancer, metastasis of cancerous solid tumors, thrombosis, restenosis following percutaneous transluminal coronary angioplasty (PTCA), rheumatoid arthritis or osteoporosis. They are also useful in systems of diagnostic and analysis. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012007562-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9474744-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009124754-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9345691-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2407478-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2555357-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10278911-B2 |
| priorityDate | 2004-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 382.